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Summary
Russia	has	one	of	the	highest	prevalences	of	paediatric	chronic	hepatitis	C	infection	
(CHC).	Our	aim	was	 to	provide	a	detailed	characterization	of	children	and	adoles-
cents	with	CHC	including	treatment	outcomes.	Thus,	an	observational	study	of	chil-
dren	with	 CHC	 aged	 <18	years	 was	 conducted	 in	 three	 hepatology	 centres	 from	
November	2014	to	May	2017.	Of	301	children	(52%	male),	196	(65%)	acquired	HCV	
vertically,	70	(23%)	had	a	history	of	blood	transfusion	or	invasive	procedures,	1	in-
jecting	drug	use	and	34	(11%)	had	no	known	risk	factors.	Median	age	at	HCV	diagno-
sis	was	3.1	[interquartile	range,	IQR	1.1,	8.2]	and	10.8	[7.4,	14.7]	at	last	follow-	up.	The	
most	common	genotype	was	1b	 (51%),	 followed	by	3	 (37%).	Over	a	quarter	of	pa-
tients	(84,	28%)	had	raised	liver	transaminases.	Of	92	with	liver	biopsy,	38	(41%)	had	
bridging	fibrosis	(median	age	10.4	[7.1,	14.1]).	Of	223	evaluated	by	transient	elastog-
raphy,	67	(30%)	had	liver	stiffness	≥5.0	kPa.	For	each	year,	increase	in	age	mean	stiff-
ness	 increased	 by	 0.09	kPa	 (95%	 CI	 0.05,	 0.13,	 P	<	0.001).	 There	 was	 significant	
correlation	between	 liver	 stiffness	and	biopsy	 results	 (Tau-	b	=	0.29,	P	=	0.042).	Of	
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial	License,	which	permits	use,	distribution	and	reproduction	
in	any	medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	commercial	purposes.
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1  | INTRODUC TION
Chronic	hepatitis	C	(CHC)	remains	one	of	the	major	causes	of	cirrho-
sis,	hepatocellular	carcinoma	and	end-	stage	liver	disease	worldwide.	
The	World	Health	Assembly	identified	hepatitis	C	as	a	global	health	
priority	 and	 in	 2016	 endorsed	 the	 Global	 Health	 Sector	 Strategy	
with	ambitious	targets	to	reduce	new	infections	by	90%	and	deaths	
by	65%	by	2030.1,2
The	World	Health	Organization	(WHO)	estimates	that	there	are	
71	million	people	living	with	hepatitis	C	virus	(HCV)	infection	(based	
on	HCV	viraemia	data),	accounting	for	1%	of	the	global	population;	
only	 20%	of	 those	 infected	 know	 about	 their	 diagnosis.	Of	 those	
who	 are	 chronically	 infected,	 15%-	30%	 progress	 to	 cirrhosis	 in	
20	years	and	399	000	people	die	annually.3,4	The	WHO	European	
region,	which	includes	the	whole	of	Europe	and	Central	Asia,	is	one	
of	the	most	affected	global	regions	with	an	estimated	chronic	HCV	
infection	prevalence	of	1.5%	and	incidence	of	62	per	100	000	pop-
ulation	per	year.4	Reliable	paediatric	estimates	are	lacking,	as	HCV	
infection in children remains largely undiagnosed.
Russia	 has	 one	 of	 the	 highest	 burdens	 of	HCV	 infection	 glob-
ally	with	an	estimated	seroprevalence	of	4.3%	and	the	highest	ab-
solute number of chronic infections of 3.2 million.5	In	2013,	a	CHC	
prevalence	of	336	per	100	000	population	was	reported	in	the	HCV	
national	surveillance	system,	reaching	670	per	100	000	in	some	re-
gions;	overall	CHC	incidence	was	40	per	100	000	per	year	but	var-
ied widely across regions, from 13 to 68.6 Over the last few years, 
the	reported	CHC	incidence	has	gradually	decreased	to	35-	36	per	
100	000	 in	 2016-	2017.7	 Genotype	 (GT)	 1b	 is	 the	 most	 prevalent	
genotype	accounting	for	55%	of	all	cases,	followed	by	GT3	(35%).8
In	 2013,	 the	 reported	 CHC	 prevalence	 was	 14	 per	 100	000	
children	aged	1-	14,6	with	 the	corresponding	 incidence	of	1.75	per	
100 000 children.9	Similar	to	adults,	there	is	a	downward	trend	ob-
served	over	the	last	years	with	the	reported	incidence	of	1.33-	1.44	
per	100	000	children	in	2016-	2017.7 Vertical transmission was the 
most	common	mode	of	acquisition	accounting	for	two-	thirds	of	new	
infections,	with	 anti-	HCV	 prevalence	 among	 pregnant	women	 re-
ported	as	1.3%	in	2011-	2012.6 Route of transmission was not deter-
mined	for	21%	of	all	infected	children	aged	≤14	years.6
Our	aim	was	 to	provide	a	detailed	characterization	of	 children	
and	adolescents	with	chronic	HCV	with	regard	to	mode	of	acquisi-
tion,	HCV	genotype,	clinical	status,	type	of	treatment	and	treatment	
outcomes	in	three	paediatric	hepatology	centres	in	Russia	in	the	pre	
direct-	acting	antivirals	(DAA)	era.
2  | MATERIAL S AND METHODS
An observational study of children and adolescents with chronic 
HCV	followed	up	in	three	Russian	hepatology	centres	was	conducted	
in	November	2014	to	July	2015.	The	participating	centres	covered	
three	 distinct	 geographical	 regions:	 the	 Children's	 Scientific	 and	
Clinical	Center	of	 Infectious	Diseases,	St.	Petersburg,	the	National	
Scientific	and	Practical	Center	of	Children's	Health,	Moscow,	and	the	
Krasnoyarsk	State	Medical	University.
A total of 100 children seen consecutively in each centre and 
meeting eligibility criteria were included.10 The eligibility criteria 
were	diagnosis	with	chronic	HCV	aged	<18	years	and	being	in	rou-
tine	follow-	up	at	the	participating	centres.
Pseudonymized	individual-	patient	data	were	retrospectively	col-
lected	according	to	a	standard	protocol	using	the	secure,	web-	based	
REDCap	electronic	data	capture	tool.11 Additional data collection on 
treatment	response	and	adverse	events	for	the	sub-	group	of	children	
still	undergoing	treatment	in	July	2015	was	conducted	prospectively	
until	May	2017,	to	obtain	treatment	outcome	data.
Ethics	 approval	 for	 the	 study	was	 obtained	 from	 the	National	
Scientific	and	Practical	Center	of	Children's	Health	of	the	Ministry	
of	Health	of	the	Russian	Federation,	Moscow.
2.1 | Definitions
Chronic	HCV	was	defined	as	detectable	HCV	RNA	in	two	or	more	
blood	samples	at	least	6	months	apart.	For	children	not	vertically	in-
fected, duration of diagnosed infection was calculated as time from 
date of diagnosis.
The	 mode	 of	 transmission	 was	 reported	 by	 participating	
clinics	 as	 vertical	 (mother	 is	 known	 to	 have	 HCV),	 suspected	
205	 treated	with	 IFN-	based	 regimens,	 100	 (49%)	 had	 SVR24.	Most	 children	 (191,	
93%)	experienced	adverse	reactions,	leading	to	treatment	discontinuation	in	6	(3%).	
In	conclusion,	a	third	of	children	acquired	HCV	via	nonvertical	routes	and	a	substan-
tial	 proportion	of	 those	with	 liver	 biopsy	 had	 advanced	 liver	 disease.	Only	 half	 of	
children	 achieved	SVR24	with	 IFN-	based	 regimens	highlighting	 the	need	 for	more	
effective	and	better-	tolerated	treatments	with	direct-	acting	antivirals.	Further	stud-
ies	are	warranted	in	Russia	on	causes	and	prevention	of	nonvertical	transmission	of	
HCV	in	children.
K E Y W O R D S
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healthcare-	associated	infection	(history	of	receipt	of	the	blood	prod-
ucts	or	invasive	procedures	in	healthcare	settings	and	no	maternal	
history	of	HCV),	injecting	drug	use	or	unknown.
Normal	ranges	of	alanine	aminotransferase	(ALT)	and	aspartate	
aminotransferase	(AST)	are	age-	dependent	and	changed	during	the	
study	period.	We	used	 the	cut-	off	 for	AST	and	ALT	of	40	IU/L,	 to	
allow	comparison	with	the	literature.	The	lower	limits	of	normal	for	
albumin	were	taken	as	35	g/L,	platelets	150	×	109/L.12
Liver	biopsy	scoring	systems	Knodell	and	Metavir	were	used	for	
liver	fibrosis	staging,	which	was	categorized	as	no	fibrosis,	portal	fi-
brosis	(Knodell	fibrosis	score	1,	Metavir	F1),	bridging	or	significant	fi-
brosis	(Knodell	fibrosis	score	3,	Metavir	F2-	3)	and	cirrhosis	(Knodell	
fibrosis	 score	 4,	Metavir	 F4).13,14	 Liver	 biopsies	 were	 reviewed	 at	
each	centre	by	experienced	histopathologists.
Results	of	liver	stiffness	evaluated	by	transient	elastography	(TE)	
were	categorized	as	normal	(<5.0	kPa),	mild	increase	(5.0	to	<7.0	kPa),	
moderate	 (7.0	 to	 <9.0	kPa)	 and	 severe	 increase	 (≥9.0	kPa);	 ≥9	kPa	
was	taken	as	predictor	of	severe	fibrosis	(≥F3).15,16
Successful	 outcome	 was	 defined	 as	 sustained	 virological	 re-
sponse	24	weeks	after	the	end	of	treatment	(SVR24).
Heights	were	converted	to	height-	for-	age	z-	scores	 (HAZ)	using	
the	WHO	Growth	Standard	for	measurements	at	age	<5	years	old,17 
and	WHO	2007	growth	reference	at	age	5-	18	years.18
2.2 | Statistical analysis
Categorical	data	were	summarized	as	frequency	(percentage)	and	con-
tinuous	data	as	median	[interquartile	range	(IQR)]	or	means	(standard	
deviations,	 SD).	 Univariable	 comparisons	 of	 characteristics	 accord-
ing	to	last	liver	biopsy	result,	last	TE	result	and	SVR24	were	assessed	
using	the	chi-	square,	Fisher's	exact,	Mann-	Whitney	or	Kruskal-	Wallis	
test,	as	appropriate.	In	analyses	of	age	and	duration	of	infection,	the	
continuous forms of the variables were used to determine whether 
age	differed	across	groups.	Correlation	between	levels	of	 liver	stiff-
ness	from	TE	and	degree	of	fibrosis	measured	by	liver	biopsy	was	as-
sessed	in	children	who	had	both	procedures	within	a	12-	month	period	
using	Kendall's	Tau-	b	correlation	coefficient.	Multivariable	analysis	of	
liver	stiffness	from	all	TE	scans	was	carried	out	using	a	linear	random	
effects	model	 to	allow	for	correlation	 in	 repeated	measurements	 in	
individuals.	The	model	assessed	the	association	between	age	at	TE,	
sex,	genotype,	centre	and	mode	of	infection.
Analyses	 were	 conducted	 using	 STATA/IC	 15.1	 (Stata	 Corp,	
College	Station,	TX,	USA).
3  | RESULTS
A	 total	 of	 301	 children	 under	 follow-	up	 were	 included	 101	 were	
from	Moscow,	 100	 from	 St	 Petersburg	 and	 100	 from	 Krasnoyarsk	
(Supporting	 information	Table	S1).	Half	were	male	 (156,	52%),	most	
were	of	white	ethnicity	(281,	93%),	and	born	in	Russia	(297,	99%).	The	
most	common	mode	of	infection	was	vertical	(196,	65%)	followed	by	
suspected	healthcare-	associated	infection	(70,	23%;	of	these	39	were	
reported	to	be	linked	to	receipt	of	blood	products,	31	had	a	history	of	
invasive	procedures	with	three	patients	having	a	history	of	cancer);	the	
rest	were	one	injecting	drug	use	and	34	(11%)	with	unknown	modes	
of	acquisition.	Median	age	at	diagnosis	of	HCV	infection	was	1.7	years	
[IQR,	0.7,	3.7]	in	those	vertically	infected,	9.2	[6.2,	12.6]	years	in	those	
with	 suspected	 healthcare-	associated	 infection	 and	 8.2	 [4.4,	 13.1]	
years	in	those	with	other	or	unknown	mode	of	infection.	Most	chil-
dren	had	genotype	1b	(155,	51%)	or	3	(111,	37%).	A	higher	proportion	
of	nonvertically	infected	children	were	clinically	symptomatic	at	HCV	
testing, had elevated liver transaminases or were screened before in-
vasive	procedures	(Supporting	information	Table	S2).
At	last	follow-	up,	in	children	with	vertical,	suspected	healthcare-	
associated	 and	 other/unknown	 modes	 of	 infection,	 respectively,	
median	 age	 was	 8.9	 [6.0,	 11.8],	 15.2	 [12.7,	 17.3]	 and	 12.5	 [10.7,	
17.5]	years	and	duration	of	diagnosed	 infection	was	6.0	 [3.0,	8.4],	
4.2	[2.5,	7.9]	and	3.5	[1.8,	7.0].	Six	vertically	infected	children	were	
HIV-	coinfected;	 one	 with	 suspected	 nosocomial	 infection	 was	
HBV-	coinfected.
3.1 | Laboratory investigations
At	 last	 visit,	 82	 (27%)	 children	 had	 ALT	 >40	IU/L,	 88	 (29%)	 AST	
>40	IU/L	 (108	 (36%)	 had	ALT	 >40	IU/L	 or	AST	 >40	IU/L),	 six	 (2%)	
had	platelets	<150	×	109/L	and	15	(5%)	had	albumin	<35	g/L.	No	dif-
ferences were observed by duration of infection/age in vertically 
infected children or duration of diagnosed infection in nonvertically 
infected.
3.2 | Liver ultrasound
All	children	had	liver	ultrasound	results	reported.	At	last,	ultrasound	
171	 (57%)	had	normal	 liver,	113	 (38%)	had	 increased	echogenicity,	
96	(32%)	heterogeneous	structure	(86	(29%)	had	both),	11	(4%)	had	
steatosis	and	15	(5%)	had	signs	of	portal	hypertension.
3.3 | Liver biopsy
Ninety-	two	(31%)	children	had	a	liver	biopsy	(four	children	had	two),	
with	median	age	at	last	biopsy	of	9.4	[IQR	6.1,	13.0]	years	(Table	1).	
The	likelihood	of	having	had	a	liver	biopsy	increased	with	age;	at	last	
follow-	up	six	of	52	 (12%)	children	aged	<5	years	had	had	a	biopsy	
compared	to	27	of	102	(26%)	6-	to	10-	year-	olds,	31	of	92	(34%)	11-	
to	15-	year-	olds	and	28	of	55	(51%)	aged	>15	years	(P	<	0.001).	Forty-	
two	 (21%)	vertically	 infected	children	had	a	biopsy	vs	50	 (48%)	of	
those with nonvertical infection but this difference was nonsignifi-
cant after adjusting for age (P	=	0.898).	There	was	significant	varia-
tion	by	centre	with	68	(67%)	of	children	at	the	Moscow	centre	having	
had	a	biopsy	compared	to	11	(11%)	in	St	Petersburg	and	13	(13%)	in	
Krasnoyarsk	(P	<	0.001).
At	last	biopsy,	38	(41%)	had	signs	of	bridging	fibrosis;	median	age	
at	 diagnosis	was	10.4	 [7.1,	 14.1]	 years,	with	 range	of	 2.1-	17.8	years.	
Cirrhosis	was	identified	at	liver	biopsy	in	one	15-	year-	old	adolescent	
in	whom	infection	acquired	through	contaminated	blood	products	was	
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diagnosed	7	months	prior	to	biopsy.	Rates	of	bridging	fibrosis	or	cirrho-
sis	at	the	last	biopsy	are	summarized	in	Table	1.
3.4 | Transient elastography
A	total	of	345	TE	measurements	were	reported	in	223	(74%)	chil-
dren.	Results	of	the	last	TE	are	summarized	in	Table	2.	There	was	
a	 significant	association	between	older	age	at	TE	and	 increased	
liver stiffness (r	=	0.22,	P	=	0.001)	 (Figure	1).	Moderate	 increase	
in	 liver	 stiffness	 (≥7	kPa)	 was	 not	 seen	 in	 children	 <7.5	years	
of age.
In	84	children	with	>1	TE,	median	time	between	first	and	last	TE	
was	18.7	[6.4,	19.5]	months.	In	patients	with	≥1	TE	who	completed	
treatment	before	 the	 last	TE,	mean	 liver	 stiffness	decreased	 from	
TABLE  1 Bridging	fibrosis	and	cirrhosis	detected	on	liver	biopsy	by	patient	characteristics
All with liver biopsy No bridging fibrosis Bridging fibrosis or cirrhosis P- value
N (%) or median [IQR]
All 92 53 (58) 39 (42)
Sex
Male 44 (48) 24 (55) 20 (45) 0.569
Female 48 (52) 29 (60) 19 (40)
Mode of infection
Vertically infected 42 (46) 27	(64) 15 (36) 0.235
Not vertically infected 50 (54) 26 (52) 24 (48)
HCV	genotype
1a/b 64	(70) 35 (55) 29 (45) 0.391
2/3 28 (30) 18 (64) 10 (36)
Centre
Moscow 68	(74) 38 (56) 30 (44) 0.181
St	Petersburg 11 (12) 9 (82) 2 (18)
Krasnoyarsk 13 (14) 6 (46) 7	(54)
All	patients
Age	at	biopsy,	Median	[IQR] 9.4	[6.1,	13.0] 8.8	[6.0,	12.2] 10.2	[7.1,	14.1] 0.179
≤5	y 21 (23) 13 (62) 8 (38)
6-	10	y 35 (38) 21 (60) 14 (40)
11-	15	y 27	(29) 14 (52) 13 (48)
>15	y 9 (10) 5 (56) 4 (44)
Vertically	infected	(n	=	42)
Duration	of	infection/age	at	biopsy,	
Median	[IQR]
6.3	[4.7,	9.0] 6.1	[4.5,	7.3] 7.8	[5.0,	10.2] 0.185
≤5	y 18 (43) 12	(67) 6 (33)
6-	10	y 18 (43) 12	(67) 6 (33)
>10	y 6 (14) 3 (50) 3 (50)
Nonvertically	infected	(n	=	50)
Age	at	biopsy,	Median	[IQR] 11.8	[9.3,	14.8] 11.8	[9.2,	14.8] 11.7	[9.5,	14.8] 0.892
≤5	y 3 (6) 1 (33) 2	(67)
6-	10	y 17	(34) 9 (53) 8	(47)
11-	15	y 22 (44) 12 (55) 10 (45)
>15	y 8 (16) 4 (50) 4 (50)
Duration of diagnosed infection at 
biopsy,	Median	[IQR]
1.9	[0.5,	8.8] 6.2	[1.2,	10.5] 0.6	[0.4,	2.9] 0.019
≤5	y 31 (62) 12 (39) 19 (61)
6-	10	y 11 (22) 9 (82) 2 (18)
>10	y 8 (16) 5 (63) 3	(27)
IQR,	interquartile	range.
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TABLE  2  Increased	liver	stiffness	detected	on	TE	by	patient	characteristics
All with TE No increase (<5 kPa)
Mild increase (5 
to <7 kPa)
Moderate or severe 
increase (≥7 kPa) P- value
n (%) or median [IQR]
All	patients 223 156	(70) 59 (26) 8 (4)
Sex
Male 110 (49) 84	(76) 22 (20) 4 (4) 0.096
Female 113 (51) 72	(64) 37	(33) 4 (4)
Mode of infection
Vertically infected 160	(72) 119	(74) 36 (23) 5 (3) 0.072
Not vertically infected 63 (28) 37	(59) 23	(37) 3 (5)
HCV	genotype
1a/b 121 (55) 86	(71) 31 (26) 4 (3) 0.929
2/3 100 (45) 69 (69) 27	(27) 4 (4)
Centre
Moscow 61	(27) 30 (49) 24 (39) 7	(11) <0.001
St	Petersburg 70	(31) 52	(74) 17	(24) 1 (1)
Krasnoyarsk 92 (41) 74	(80) 18 (20) 0
All	patients
Age	at	the	last	TE,	Median	[IQR] 9.0	[6.3,	13.2] 8.5	[6.0.12.1] 10.7	[6.9,	15.1] 14.6	[11.4,	16.7] 0.003
≤5	y 51 (23) 39	(76) 12 (24) 0
6-	10	y 88 (39) 68	(77) 18 (20) 2 (2)
11-	15	y 53 (24) 33 (62) 17	(32) 3 (6)
>15	y 31 (14) 16 (52) 12 (38) 3 (10)
Vertically	infected	(n	=	160)
Duration of infection/age at the 
last	TE,	Median	[IQR]
7.7	[5.5,	11.0] 7.6	[5.4,	9.9] 8.0	[5.3,	12.9] 13.2	[9.6,	14.1] 0.066
≤5	y 48 (30) 37	(77) 11 (23) 0
6-	10	y 72	(45) 57	(79) 13 (18) 2 (3)
11-	15	y 31 (19) 22	(71) 7	(23) 2 (6)
>15	y 9 (6) 3 (33) 5 (56) 1 (11)
Nonvertically	infected	(n	=	63)
Age	at	the	last	TE,	Median	[IQR] 13.2	[9.4,	17.0] 12.8	[8.8,	16.6] 13.5	[9.5,	17.0] 16.9	[15.1,	17.3] 0.353
≤5	y 3 (5) 2	(67) 1 (33) 0
6-	10	y 16 (25) 11 (69) 5 (31) 0
11-	15	y 22 (35) 11 (50) 10 (45) 1 (5)
>15	y 22 (35) 13 (59) 7	(32) 2 (9)
Duration of diagnosed infection 
at	the	last	TE,	Median	[IQR]
8.5	[2.8,	12.8] 8.5	[3.4,	12.1] 8.6	[1.8,	13.1] 2.7	[0.6,	9.1] 0.429
≤5	y 25 (40) 15 (60) 8 (32) 2 (8)
6-	10	y 19 (30) 10 (53) 8 (42) 1 (5)
>10	y 12 (19) 7	(58) 5 (42) 0
>15	y 7	(11) 5	(71) 2 (29) 0
Treatment	status	at	the	last	TE	(n	=	223)
Not commenced 126	(57) 89	(71) 35 (28) 2 (2) 0.026
Treatment ongoing 15	(7) 6 (0) 8 (53) 1	(7)
Treatment	complete 82	(37) 61	(74) 16 (20) 5 (6)
IQR,	interquartile	range;	TE,	transient	elastography.
6  |     TURKOVA eT Al.
5.2	(SD	1.7)	to	4.6	(SD	1.6)	between	the	first	and	last	TE	(P	<	0.001)	
(Supporting	Information	Figure	S3).
In	multivariable	random	effects	analysis	of	all	available	TE	results,	
there was no association between mode of infection (P	=	0.577),	sex	
(P	=	0.625)	and	genotype	(P	=	0.269)	but	for	every	1	year	increase	in	
age	at	TE	mean	stiffness	increased	by	0.09	kPa	(95%	CI	0.05,	0.13,	
P	<	0.001).	Mean	liver	stiffness	was	1.1	kPa	(0.7,	1.5,	P	<	0.001)	lower	
at	both	St	Petersburg	and	Krasnoyarsk	centres	than	in	Moscow.
3.5 | Comparison of biopsy and transient 
elastography results
Sixty-	four	children	had	both	a	biopsy	and	a	scan.	For	34,	scanning	oc-
curred	within	a	year	of	a	biopsy	(Figure	2),	with	a	significant	but	rela-
tively	weak	correlation	between	TE	and	biopsy	results	(Tau-	b	=	0.29,	
P	=	0.042).	 In	 the	 three	patients	with	 fibrosis	 stage	F0,	TE	 ranged	
from	3	to	4.2	kPa.	In	20	patients	with	stage	F1	median	stiffness	was	
4.9	[4.4,	5.5],	range	3.4-	8.3	kPa	and	in	11	patients	with	stage	F2	was	
5.4	 [4.0,	7.1],	 range	3.3-	7.5	kPa.	No	children	with	F3	or	F4	had	TE	
results	reported.
3.6 | Treatment
Overall,	205	(68%)	children	received	treatment,	most	commonly	pe-
gylated	interferon	(PegIFN)	alfa-	2b	and	ribavirin	(RBV);	37	(18%)	re-
ceived	>1	treatment	course.	Median	duration	was	16	[14,	28]	months.	
Indications for the last treatment were evidence of fibrosis on liver 
biopsy	or	TE	in	62	(30%),	elevated	ALT	with	no	fibrosis	in	60	(29%)	
and	family	preference	in	83	(40%).	Most	treated	children	(191/205,	
93%)	experienced	adverse	reactions,	most	commonly	flu-	like	symp-
toms	 (Table	3).	 Six	 children	 required	 treatment	 with	 antidepres-
sants	and	one	required	thyroxin	replacement.	Across	all	205	treated	
children,	 54	 (26%)	 had	 dose	 reduction	 and/or	 discontinuation.	
Thirty-	nine	(19%)	children	prematurely	discontinued	the	last	course	
of	treatment:	33	(16%)	for	inadequate	response	and	6	(3%)	for	drug	
reactions.
HCV	 results	 24	weeks	 post-	treatment	 discontinuation	 were	
available	 for	 all	 treated	 patients,	 100	 (49%)	 of	 whom	 had	 SVR24	
(Table	3).	 SVR24	 was	 achieved	 in	 6	 children	 (46%)	 treated	 with	
IFN	alfa-2a/b/RBV,	22	(37%)	treated	with	IFN	alfa-2a/b	only	and	7	
(37%)	on	other	treatments	(Table	3).	Of	those	treated	with	PegIFN	
alfa-2b/RBV,	65	(57%)	achieved	SVR24	overall	(35	(55%)	with	GT1,	
and	 30	 (61%)	with	GT2/3)	 (Table	4).	 SVR24	was	more	 common	 in	
those vertically infected (P	=	0.014),	but	the	difference	disappeared	
after adjusting for age at treatment start (P	=	0.216).	Nonvertically	
infected children also had a higher rate of treatment discontinua-
tion	 (Supporting	 information	 Table	 S2).	 Treatment	 outcomes	 var-
ied	 significantly	 by	 centre,	with	 the	 lowest	 proportion	of	 patients	
with	SVR24	in	Moscow	(34%)	and	the	highest	in	Krasnoyarsk	(74%)	
(Supporting	 information	 Table	 S1).	 The	Moscow	 cohort	 had	more	
complex	patients,	more	patients	diagnosed	at	older	ages	and	more	
with	clinical	symptoms	or	elevated	transaminases	at	diagnosis.	More	
patients	 in	Moscow	also	had	 increased	 liver	stiffness	measured	by	
TE	and	bridging	fibrosis	on	liver	biopsy	suggesting	more	progressive	
disease	 (Tables	1	 and	 2;	 Supporting	 information	 Table	 S1).	 Higher	
treatment	discontinuations	 in	 the	Moscow	cohort	 (31%	vs	15%	St	
Petersburg	and	8%	Krasnoyarsk)	(Supporting	information	Table	S1)	
also	partially	explain	the	centre	differences	in	cure	rates.
Of the 205 treated children, 193 had height data at the start and 
end	of	treatment.	At	treatment	start,	mean	HAZ	was	−0.03	(SD	1.13)	
and z-	scores	decreased	during	treatment	(mean	change	−0.11	[95%	
CI	−1.18,	−0.29]).	 In	children	on	PegIFN	alfa-	2b/RBV	mean	z-	score	
was	−0.12	(1.15)	and	decreased	by	−0.09	(95%	CI	−0.19,	0.01)	during	
treatment. Change in z-	scores	did	not	vary	significantly	by	treatment	
type	(P	=	0.326).	The	largest	decreases	in	z-	scores	were	observed	in	
children	aged	10-	15	years	(−0.17	[95%	CI	−0.23,	−0.09])	followed	by	
F IGURE  1 Age at transient 
elastography	(TE)	by	degree	of	liver	
stiffness. Association between age and 
liver	stiffness	measured	using	TE	in	223	
children	with	HCV	in	Russia.	There	was	a	
significant	positive	association	between	
age and liver stiffness (r	=	0.22,	P	=	0.001)
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6-	to	10-	year-	olds	(−0.12	[−0.23,	−0.02])	and	under	5s	(−0.10	[−0.42,	
0.22])	with	no	change	in	those	15	years	or	more	at	treatment	start	
(0.05	[−0.02,	0.12]).
4  | DISCUSSION
Russia	has	one	of	the	largest	populations	of	children	living	with	HCV	
in	Europe;	however	there	are	scarce	data	on	CHC	in	children	in	peer-	
reviewed	literature	published	outside	Russia.	This	study	contributes	
to	addressing	this	knowledge	gap	by	providing	detailed	characteri-
zation	of	a	large	number	of	children	and	adolescents	with	CHC,	of	
whom	65%	were	vertically	infected.
The	most	 frequent	 reason	 for	HCV	 testing	was	HCV	 infection	
in a family member, usually the mother, which coincided with the 
predominance	 of	 vertical	 mode	 of	 transmission	 in	 the	 study	 and	
with national surveillance data.6	Vertical	transmission	of	HCV	so	far	
remains	 the	 only	 nonpreventable	 route	 of	 acquisition	 of	 hepatitis	
C	 infection	 in	 children.	 Notably,	 the	 observed	 proportion	 of	 ver-
tical	 infection	 is	 lower	here	compared	to	 that	 reported	 in	western	
European	children.19
The	 finding	 that	 infection	 possibly	 acquired	 via	 transfusion	
of	blood	components	or	through	invasive	procedures	comprised	
nearly	a	quarter	of	all	cases	here	is	important.	In	the	national	sur-
veillance	 report,	 a	 similar	 proportion	 of	 children	 had	 unknown	
mode of transmission.6	 A	 recent	 outbreak	 of	 hospital-	acquired	
HCV	 infection	 at	 a	 Russian	 children's	 hospital	 in	 the	 Amur	 re-
gion	 highlights	 the	 significance	 of	 the	 problem.20	 Healthcare-	
associated	 HCV	 infections	 are	 almost	 impossible	 to	 confirm	
retrospectively.	History	of	invasive	healthcare	procedures,	when	
vertical	 transmission	 is	 ruled	out,	 can	be	 considered	 as	 a	 proxy	
of	 healthcare-	associated	 infections	 in	 children	 and	 younger	 ad-
olescents, as other routes of transmission such as cosmetic 
procedures	 (piercing	 and	 tattooing),	 sexual	 transmission	and	 in-
jecting	drug	use,	are	extremely	rare	in	this	age	group.	Suspected	
healthcare-	associated	HCV	 infections	 in	children	can	serve	as	a	
sentinel	of	possible	ongoing	transmission	of	blood-	borne	patho-
gens in health care settings.
Distribution	of	HCV	genotypes	 in	 children	here	was	 similar	 to	
the	distribution	reported	in	the	national	reports,6,8	with	GT1b	being	
a	predominant	genotype,	followed	by	GT3.	Genotype	distribution	in	
adults	 is	associated	with	mode	of	transmission,	with	GT1a,	3a	and	
4	being	mostly	IDU	related	and	GT1b	and	2	associated	with	blood	
transfusion	and	unsafe	medical	procedures.21
Among	those	with	liver	biopsy,	we	found	liver	disease	progres-
sion,	including	to	bridging	fibrosis	in	41%	of	children	and	cirrhosis	in	
one	15-	year-	old	adolescent,	and	nearly	half	of	children	aged	older	
than 10 years had bridging fibrosis. Notably, children as young as 
2-	5	years	of	age	had	bridging	fibrosis	highlighting	rapid	progression	
at	 young	 age	 in	 a	minority.	As	 determinants	 of	 liver	 disease	 pro-
gression are uncertain, genetic and other host factors could have 
had	an	 impact	on	 the	particularly	 aggressive	 course	of	disease	 in	
some	children.	Only	 a	 third	of	 children	had	a	 liver	biopsy,	 poten-
tially	reflecting	selection	bias	of	choosing	children	with	suspected	
advanced	 liver	 disease	 for	 the	 invasive	 staging.	 However,	 in	 our	
study	TE	was	 introduced	from	2008	to	2011	 in	different	centres,	
and	prior	to	this	 liver	biopsy	was	the	only	method	of	staging	liver	
disease.	Differences	 in	 local	practices	 and	complexity	of	patients	
likely	played	a	role	as	most	children	with	liver	biopsy	attended	the	
Moscow	 centre.	We	did	 not	 find	 a	 relationship	 between	 age	 and	
advanced	liver	disease;	however,	likelihood	of	liver	biopsy	increased	
with	age	and	it	 is	 likely	that	younger	children	undergoing	biopsies	
did	 so	 based	 on	 non-	invasive	 tests	 suggestive	 of	 liver	 disease.	
Overall,	high	proportions	of	children	with	bridging	fibrosis	on	liver	
biopsy	here	indicate	that	a	substantial	proportion	of	children	with	
CHC	have	advanced	liver	disease.
F IGURE  2 Comparison	of	liver	
stiffness measured using transient 
elastography	(TE)	and	fibrosis	stage	from	
liver	biopsy.	Association	between	liver	
stiffness	measured	using	TE	and	fibrosis	
stage	determined	from	liver	biopsy	in	34	
children	with	HCV	in	Russia	who	had	a	
liver	biopsy	within	1	y	of	a	TE.	There	was	
a significant correlation between liver 
stiffness	and	biopsy	results	(Tau-	b	=	0.29,	
P	=	0.042)
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Three-	quarters	of	children	had	evaluation	of	liver	stiffness	by	TE,	
used	as	 indirect	assessment	of	 liver	fibrosis.	Greater	 liver	stiffness	
was observed with older age and duration of infection, although only 
two	(1%)	children	had	liver	stiffness	indicative	of	advanced	fibrosis	
(≥9	kPA)	and	six	(3%)	had	a	moderate	increase	(7	to	<9	kPa);	7%	of	
children over 10 years of age had a moderate or severe increase. The 
paired	TE	and	liver	biopsy	results	were	available	for	children	with	ini-
tial	stages	of	liver	disease	(F0-	F2);	no	children	with	F3	or	F4	had	TE	
as	all	of	them	had	liver	biopsy	before	TE	was	introduced	in	the	cen-
tres.	This	could	be	a	possible	explanation	for	the	weak	correlation	
between	TE	and	liver	biopsy	results	here.	Drawbacks	of	using	TE	for	
evaluation	of	liver	disease	staging	have	high	inter-	patient	variation,	
lack	 of	 correlation	 between	 TE	 and	 liver	 biopsy	 for	 nonadvanced	
liver	fibrosis	and	absence	of	validated	data	for	children	with	CHC.22 
High	inter-	and	intra-	observer	variability	of	liver	biopsy	evaluation23 
and	 different	 biopsy	 scoring	 systems	 add	 to	 these	 limitations.	 At	
TABLE  3 Treatment duration, discontinuations, adverse events and outcomes
All
PegIFN alfa- 2b and 
ribavirin
IFN alfa- 2a/b plus 
ribavirin IFN alfa- 2a/b only Other
n (%) or median [IQR]
Total 205 114 13 59 19
Duration of treatment (mo)
All 16	[14,	28] 21	[14,	28] 17	[14,	18] 16	[14,	28] 15	[11,	27]
Genotype	1a/b 28	[16,	28] 28	[28,	28] 16	[14,	23] 17	[15,	28] 27	[8,	28]
Genotype	2/3 14	[14,	15] 14	[14,	14] 15	[14,	17] 15	[14,	26] 15	[14,	16]
Treatment	prematurely	
discontinued
39 (19) 12 (11) 3 (23) 18 (31) 6 (32)
Reasons	for	premature	discontinuationa
Inadequate	response 33 (85) 8	(67) 2	(67) 17	(94) 6 (100)
Drug reactions 6 (15) 5 (42) 0 0 1	(17)
Family	decision 8 (21) 4 (33) 2	(67) 2 (11) 0
Side	effectsa
None 14	(7) 1 (1) 2 (15) 10	(17) 1 (5)
Hypersensitivity	reaction 6 (3) 6 (5) 0 0 0
Diarrhoea 6 (3) 5 (4) 0 1 (2) 0
Nausea/vomiting 20 (10) 17	(15) 1 (8) 2 (3) 0
Hepatotoxicity 4 (2) 2 (2) 0 1 (2) 1 (5)
Hypothyroidism 2 (1) 2 (2) 0 0 0
Hair	loss 39 (19) 34 (30) 1 (8) 4	(7) 0
Poor weight gain/weight 
loss
48 (23) 36 (40) 0 10	(17) 2 (11)
Insomnia 34	(17) 26 (22) 1 (8) 7	(12) 0
Depression/anxiety 32 (16) 19	(17) 1 (8) 10	(17) 2 (11)
Flu-	like	symptoms 186 (91) 110 (96) 11 (85) 48 (81) 17	(89)
Weakness 79	(39) 54	(47) 3 (23) 19 (32) 3 (16)
Local reaction at injection 
site
114 (56) 74	(65) 1 (8) 25 (42) 14	(74)
Anaemia 46 (22) 34 (30) 0 10	(17) 2 (11)
Thrombocytopenia 21 (10) 14 (12) 0 4	(7) 0
Neutropenia 59 (29) 40 (35) 0 15 (25) 4 (21)
Other 21 (10) 19	(17) 0 2 (3) 0
SVR24
All 100 (49) 65	(57) 6 (46) 22	(37) 7	(37)
IQR,	interquartile	range.
aMore	than	one	adverse	event	or	discontinuation	reason	may	be	reported	in	the	same	child.	Multiple	adverse	events	were	reported	in	the	six	children	
who	discontinued	due	to	drug	reactions	including	hypersensitivity	(n	=	2),	weakness	(n	=	2),	depression/anxiety	(n	=	4),	anaemia	(n	=	2),	alopecia	(n	=	3)	
and	insomnia	(n	=	1).	
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present,	it	is	not	possible	to	confidently	identify	rapid	CHC	progres-
sors	with	non-	invasive	 tests,	and	 liver	biopsy	 remains	a	gold	stan-
dard	for	 liver	disease	staging,	despite	being	an	 invasive,	expensive	
and	operator-	dependant	procedure	requiring	technical	and	pathol-
ogy	expertise	and	general	anaesthetic	in	younger	children.	There	is	a	
pressing	need	of	a	large	high-	quality	study	validating	TE	against	liver	
TABLE  4 SVR24	by	patient	characteristics	in	all	treated	children	and	those	treated	with	PegIFN	alfa-	2b	+	ribavirin	only
ALL treated PegIFN alfa- 2b + ribavirin only
n (%) No SVR24 SVR24 P- value No SVR24 SVR24 P- value
All 205 105 (51) 100 (49) 49 (43) 65	(57)
Sex
Male 102 (50) 58	(57) 44 (43) 0.108 25 (43) 33	(57) 0.979
Female 103 (50) 47	(46) 56 (54) 24 (43) 32	(57)
Mode of infection
Vertically infected 126 (61) 56 (44) 70	(56) 0.014 36 (44) 45 (56) 0.621
Not vertically infected 79	(39) 49 (62) 30 (38) 13 (39) 20 (61)
HCV	genotypea
1a/b 125 (61) 69 (55) 56 (45) 0.129 29 (45) 35 (55) 0.486
2/3 79	(39) 35 (44) 44 (56) 19 (39) 30 (61)
Multiple	treatments
No 186 (82) 83 (49) 85 (51) 0.268 37	(42) 52 (58) 0.566
Yes 37	(18) 22 (59) 15 (41) 12 (48) 13 (52)
All	patients
Age at treatment start, 
median	[IQR]
8.9 [5.8, 
12.9]
10.0	[6.7,	14.1] 8.2	[4.7,	12.0] 0.014 10.0	[7.0,	14.1] 8.6	[6.1,	12.7] 0.435
<2	y 10 (5) 2 (20) 8 (80) 0 0
2-	5	y 45 (22) 20 (44) 25 (56) 9 (36) 16 (64)
6-	10	y 73	(36) 36 (49) 37	(51) 18 (42) 25 (58)
>10	y 77	(38) 47	(61) 30 (39) 22 (48) 24 (52)
Vertically	infected	(n	=	126)
Duration of infection/age 
at treatment start, 
median	[IQR]
7.1	[4.4,	
10.0]
7.5	[4.9,	11.3] 6.5	[4.2,	9.1] 0.146 8.7	[6.5,	11.6] 7.1	[4.7,	9.8] 0.102
<2	y 10 (8) 2 (20) 8 (80) 0 0
2-	5	y 40 (32) 17	(43) 23 (58) 7	(30) 16	(70)
6-	10	y 48 (38) 22 (46) 26 (54) 16 (46) 19 (54)
>10	y 28 (22) 15 (54) 13 (46) 13	(57) 10 (43)
Nonvertically	infected	(n	=	79)
Age at treatment start, 
median	[IQR]
11.9 [8.8, 
16.4]
12.9	[9.4,	15.9] 11.7	[8.7,	16.4] 0.824 14.1 [10.8, 
15.5]
14.1 [10.8, 
16.5]
0.854
2-	5	y 5 (6) 3 (60) 2 (40) 2 (100) 0
6-	10	y 25 (32) 14 (56) 11 (44) 2 (25) 6	(75)
>10	y 49 (62) 32 (65) 17	(35) 9 (39) 14 (61)
Duration of diagnosed 
infection at treatment 
start,	median	[IQR]
1.6	[0.7,	
6.0]
1.4	[0.6,	3.4] 2.3	[1.1,	6.6] 0.047 1.4	[1.0,	4.7] 2.3	[1.2,	8.3] 0.407
<2	y 43 (54) 31	(72) 12 (28) 9 (53) 8	(47)
2-	5	y 16 (20) 8 (50) 8 (50) 1 (25) 3	(75)
6-	10	y 16 (20) 7	(44) 9 (56) 1 (11) 8 (89)
>10	y 4 (5) 3	(75) 1 (25) 2	(67) 1 (33)
IQR,	interquartile	range.
aGenotype	unknown	for	one	patient.	
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biopsy	in	paediatric	population	with	HCV.	Our	dataset	was	insuffi-
cient	to	address	this.	A	larger	sample	of	paired	TE	and	liver	biopsy	
across	all	stages	of	liver	fibrosis	in	children	with	HCV	is	required,	and	
a	pooled	analysis	of	data	from	different	cohorts	may	be	necessary.	A	
Russian	European	alliance	for	research	among	women,	children	and	
adolescents	impacted	by	HIV,	TB	and	HCV	(REACH)	aims	to	address	
this	knowledge	gap.24
Overall,	our	study	showed	that	a	higher	proportion	of	children	
than	 previously	 thought	may	 develop	 advanced	 liver	 disease	with	
rapid	progression	in	some	children.	These	findings,	together	with	a	
few recent observational studies,25,26 challenge the traditional be-
lief	 that	HCV	 causes	 no	 health	 problems	 in	 childhood.	Our	 study	
confirms	results	of	other	small	paediatric	studies	that	older	age	and	
duration	of	infection	are	associated	with	higher	risk	of	liver	disease	
progression.27-29	Recently	presented	national	data	from	the	UK	high-
lighted	poor	mid-	term	prognosis	 in	 individuals	who	 acquired	HCV	
in	 childhood	 with	 33%	 progressing	 to	 cirrhosis	 by	 median	 age	 of	
33 years.30	 Liver	disease	progression	 in	 childhood	or	 young	adult-
hood	 in	a	substantial	proportion	of	patients	with	HCV	acquired	 in	
childhood	and	the	inability	to	identify	rapid	progressors	are	strong	
arguments	for	treating	all	children	and	adolescents	provided	effec-
tive	and	well-	tolerated	treatments	are	available.
PegIFN-	based	 treatments	 remain	 the	 only	 currently	 available	
treatment	 for	 children	 in	 Russia.	 PegIFN/RBV	 treatment	 is	 pro-
longed	(24	weeks	for	HCV	GT2,3	and	48	weeks	for	other	genotypes)	
and	invasive	(requiring	weekly	injections	of	PegIFN),	and	although	it	
is	reported	to	be	better	tolerated	by	children	compared	to	adults,31 
it	is	associated	with	substantial	toxicity	and	has	suboptimal	efficacy.	
Over	two-	thirds	of	children	in	this	study	were	treated.	Only	57%	of	
children	 treated	with	PegIFN/RBV	achieved	 SVR24,	 similar	 to	 the	
results	of	a	meta-	analysis	demonstrating	58%	of	overall	SVR	across	
genotypes;	rates	of	treatment	discontinuation	due	to	adverse	events	
were also similar.31	The	proportion	of	children	with	SVR24	was	low-
est	in	Moscow,	which	might	be	explained	by	their	more	complex	pa-
tients, and also their treatment of children from across Russia, with 
joint	follow-	up	with	local	hepatitis	C	clinics	potentially	contributing	
to	 more	 frequent	 treatment	 discontinuations.	 This	 highlights	 the	
difficulties	of	treating	children	with	prolonged	IFN-	based	schemes,	
especially	those	living	in	remote	settings.
Most	treated	children	in	our	study	experienced	adverse	events.	
Of	those	treated	with	PegIFN/RBV,	one	in	three	developed	anaemia	
or	neutropenia,	 one	 in	 three	had	hair	 loss	 and	one	 in	 six	 suffered	
from	 anxiety/depression;	 the	 latter	 may	 be	 underestimated	 given	
that young children do not understand or communicate these ad-
verse	events	well.	Consistent	with	previous	studies,32-34 we showed 
that	 growth	was	 adversely	 affected	 during	 treatment,	 particularly	
among young adolescents.
Our	results	confirm	that	currently	used	regimens	have	subop-
timal	outcomes	and	very	poor	safety	profiles.	Today,	when	DAAs	
can	achieve	cure	rates	of	more	than	95%,	it	seems	unethical	to	treat	
patients	with	IFN-	based	regimens	with	suboptimal	response	rates	
and nearly universal occurrence of adverse reactions as indicated 
by	a	93%	rate	in	this	study.	However,	only	IFN-	based	regimes	are	
currently	 approved	 for	 paediatric	 treatment	 in	Russia.	 For	DAAs	
to	be	licensed	in	children,	it	is	required	that	paediatric	studies	are	
conducted	 in	Russia	which	presents	an	additional	hurdle	 to	mak-
ing DAAs accessible to children. Clinicians, regulatory authorities 
and	the	community	health	sector	should	work	together	to	expedite	
the	process.	Outside	Russia,	at	present	only	two	drugs	 (sofosbu-
vir	and	ledipasvir)	are	licensed	for	adolescents	aged	≥12	years	by	
the	FDA	and	EMA;	paediatric	access	to	these	drugs	 is	delayed	 in	
most	 countries,	 with	 prohibitive	 costs.	 Middle-	income	 countries	
are	 in	 a	 particularly	 difficult	 situation	 as	 they	 are	 excluded	 from	
voluntary	 licensing	agreements	and	compulsory	 licensing	 is	chal-
lenging	 to	 implement.35,36	 We	 showed	 that	 patients	 completing	
treatment had a significant decrease of liver stiffness measured 
by	 TE,	 suggesting	 that	 treatment	 in	 childhood	maybe	 beneficial.	
In	the	absence	of	DAA-	regimens	for	children,	the	only	treatment	
option	 in	many	countries	are	 IFN-	based	schemes.	So,	 the	ethical	
question	remains	whether	children	with	evidence	of	 liver	disease	
progression	should	wait	for	new	regimens	or	be	treated	now	with	
suboptimal	 but	 available	 treatment.	 The	options	of	 treating	 chil-
dren	with	DAAs	within	prospective	studies	should	be	implemented	
where	possible.
Antenatal	 HCV	 screening	 is	 routine	 in	 Russia6	 and	 presents	 a	
unique	 opportunity	 for	 timely	 intervention	 to	 cure	maternal	HCV	
and	 prevent	 vertical	 transmission.	With	 currently	 available	DAAs,	
which	have	an	excellent	safety	profile,	this	could	become	a	promis-
ing	component	within	a	broader	strategy	for	eliminating	paediatric	
HCV.	Results	from	a	phase	I	safety	trial	of	sofosbuvir	and	ledipasvir	
for	pregnant	women	with	GT1	are	expected	in	2019,37 and a strategy 
trial	is	required.
This	large	study	of	children	and	adolescents	with	chronic	HCV	in	
Russia	highlights	the	important	burden	of	disease	in	this	setting	and	
the	need	to	treat	children	early	to	prevent	progression	of	liver	dis-
ease	with	more	effective	and	better-	tolerated	treatment.	Although	
treatment coverage was high, only half of those treated achieved 
SVR24.	There	is	therefore	an	urgent	need	to	speed	up	access	to	new	
DAAs,	particularly	 for	older	children	and	adolescents,	and	make	 it	
available	at	affordable	prices	in	all	settings.
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